Share price estimates for Sanofi
Paris-headquartered Sanofi (SNY) is a leading global pharmaceutical company that operates in pharmaceuticals, human vaccines, and animal health. According to a Bloomberg consensus of five brokerage firms on September 12, 2016, 60.0% of analysts rated Sanofi as a “buy,” while 40% rated the company as a “hold.”
Although the number of analysts bullish on the stock is the same as in March 2016, Sanofi’s target share price has been downgraded from the earlier consensus price of $52 on March 3, 2016. The consensus 12-month target price for Sanofi is now $49.33. This translates to a ~25.9% return, as compared to Sanofi’s closing price of $39.2 on September 13, 2016.
Analyst recommendations for peers
According to the Bloomberg survey of 26 analysts on September 12, 2016, 76.9% analysts issued a “buy” rating for Eli Lilly (LLY), whereas 23.1% suggested that the stock should be a “hold.” With a 12-month consensus target price of $98.2, Eli Lilly presents an opportunity to earn 25.5% over its closing price of $78.24 on September 9.
According to the 24 analysts rating Merck & Company (MRK) on September 12, 2016, 45.8% believed the company should be a “buy,” whereas 54.2% recommended a “hold” rating for the company. Given its 12-month consensus target price of $65.7, you could earn 5.1% over its closing price of $62.49 on September 9.
According to the Bloomberg consensus of nine analysts on September 12, 2016, 22.2% of analysts issued a “buy” rating for AstraZeneca (AZN), whereas 66.7% recommended that the stock should be a “hold.” The remaining 11.1% analysts suggested that the stock should be a “sell.” Given its closing price of $32.2 on September 9, AZN presents a return potential of 24.9% over the next 12 months.
Remember, direct investments in stocks can be risky. To mitigate such risk, careful investors often opt for ETFs like the First Trust Value Line Dividend Index Fund (FVD), which has 0.53% of its total holdings in Sanofi.